Skip to Content

Surprise Hits: Botox gets injected into the market -- and faces stiff competition

Text SizeAAA

Filed under: Company News, Columns

More

Many years ago, a friend afflicted with blepharspasm (uncontrolled blinking) told me she was about to undergo a new treatment in which the toxin that caused botulism would be injected into the muscle of her eye. I was aghast but said nothing -- until a week later, when I met her again, and her incessant blinking had miraculously stopped, to her great relief.

That was my first encounter with Botox, a drug that has become an accepted standard for facial cosmetic improvement, and something of a whipping boy for our beauty- and youth-obsessed culture. Allergan (AGN) reported 2007 sales of $1.2 billion for its drug, most often used to erase wrinkles, frown lines, and crow's feet. Botox injections run $350 to $500 a pop, and its effect lasts from up to six months.

Allergan is about to get some competition. Paris-based companies Medicis Pharmaceutical (MRX) and Ipsen sell a similar drug, Dysport, in Europe, and are seeking FDA approval to market it here under the name Reloxin. The drug is expected to undercut Botox's price, as is Johnson & Johnson (JNJ), now working through clinical trials to gain approval for its botulinum-based PurTox.

In a sense, these drugs offer a kinder, gentler plastic surgery. Botox and its rivals aren't surgical, permanent, or horribly expensive, and Botox has few documented side effects (other than occasional turtle mouth). In the end, it's not really much more self-indulgent than a good haircut or an expensive pair of shoes. It's even become a bit of a recession-era craze among some unemployed middle-aged execs who rely on its effects to improve a job search. Any realist knows you're much more likely to land a job when you look mahhhvelous.

Tom Barlow is a wrinkled writer who wonders if there is a relationship between the renewed popularity of zombie movies and the Botox craze.

Be sure to check out all 20 recent products that became Surprise Hits.

Reader Comments (Page 1 of 1)

Interest Rates

5/1 ARM+4.06%APR: +3.75%
30 Yr.
Fixed Mort.
+5.03%APR: +5.16%
$30K
HELOC
+8.00%APR: 0.00%
30 Mo
New Car Loan
+6.77%APR: 0.00%
1 Yr. CD+1.57%APR: +1.58%
DailyFinance Writers
Melly Alazraki Melly Alazraki Financial writer and analyst
James Altucher James Altucher Financial columnist
Jeff Bercovici Jeff Bercovici Media columnist
Jonathan Berr Jonathan Berr Financial writer and media columnist
Mercedes Cardona Mercedes Cardona Retail reporter
Tim Catts Tim Catts Financial writer
Peter Cohan Peter Cohan Author, venture capitalist and financial writer
Carrie Coolidge Carrie Coolidge Financial writer
Lita Epstein Lita Epstein Financial writer
Sam Gustin Sam Gustin Technology Writer
Nikhil Hutheesing Nikhil Hutheesing Tech and investing editor
Joseph Lazzaro Joseph Lazzaro Markets and economics writer
Latif Lewis Michelle Leder Financial Columnist
Latif Lewis Latif Lewis Business news editor and management columnist
Anthony Massucci Anthony Massucci Senior writer and tech columnist
Doug McIntyre Doug McIntyre Business and investing news writer and editor
Michael Mercurio Michael Mercurio Managing Editor
Todd Pruzan Todd Pruzan Features editor
Michael Rainey Michael Rainey Editor and economics writer
Alex Salkever Alex Salkever Senior technology writer
David Schepp David Schepp Business News reporter
Matthew Scott Matthew Scott Investing reporter and editor
Dan Solin Daniel R. Solin Author, investment advisor and retirement expert
Amey Stone Amey Stone Executive editor
Bruce Watson Mark Svenvold Columnist, renewable energy
Russel Turk, M.D. Russell Turk, M.D. Healthcare policy columnist
Bruce Watson Bruce Watson Features Writer
my portfolios

Find out why more people track their portfolios on AOL Money & Finance than anywhere else.

Create a New Portfolio My Portfolios

Daily Finance Partners

More from the Weblogs Network